 TEL AVIV, Israel, May 4, 2021 PRNewswire -- BioLineRx Ltd. NASDAQ: BLRX TASE: BLRX, a late clinical-stage biopharmaceutical company focused on oncology, today announced positive top-line results from the Companys GENESIS Phase 3 trial evaluating its lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor G-CSF, the standard of care in this indication, for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients. 